JP2018186833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018186833A5 JP2018186833A5 JP2018149864A JP2018149864A JP2018186833A5 JP 2018186833 A5 JP2018186833 A5 JP 2018186833A5 JP 2018149864 A JP2018149864 A JP 2018149864A JP 2018149864 A JP2018149864 A JP 2018149864A JP 2018186833 A5 JP2018186833 A5 JP 2018186833A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein consisting
- composition
- amount
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/663,527 | 2012-10-30 | ||
| US13/663,527 US10028998B2 (en) | 2012-10-30 | 2012-10-30 | Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538506A Division JP6423351B2 (ja) | 2012-10-30 | 2013-10-30 | Ｆｃγ受容体ＩＩＢ変異体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018186833A JP2018186833A (ja) | 2018-11-29 |
| JP2018186833A5 true JP2018186833A5 (enExample) | 2019-01-17 |
Family
ID=49679480
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538506A Active JP6423351B2 (ja) | 2012-10-30 | 2013-10-30 | Ｆｃγ受容体ＩＩＢ変異体 |
| JP2018149864A Pending JP2018186833A (ja) | 2012-10-30 | 2018-08-09 | Ｆｃγ受容体ＩＩＢ変異体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538506A Active JP6423351B2 (ja) | 2012-10-30 | 2013-10-30 | Ｆｃγ受容体ＩＩＢ変異体 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10028998B2 (enExample) |
| EP (1) | EP2914624B1 (enExample) |
| JP (2) | JP6423351B2 (enExample) |
| KR (1) | KR102170674B1 (enExample) |
| CN (1) | CN104918955B (enExample) |
| AU (1) | AU2013340831B2 (enExample) |
| BR (1) | BR112015008815A2 (enExample) |
| CA (1) | CA2887164C (enExample) |
| CL (1) | CL2015001127A1 (enExample) |
| DK (1) | DK2914624T3 (enExample) |
| EA (1) | EA033437B9 (enExample) |
| ES (1) | ES2628049T3 (enExample) |
| HR (1) | HRP20170894T1 (enExample) |
| HU (1) | HUE032786T2 (enExample) |
| IL (1) | IL238528A (enExample) |
| IN (1) | IN2015DN03206A (enExample) |
| LT (1) | LT2914624T (enExample) |
| MX (1) | MX359802B (enExample) |
| MY (1) | MY173686A (enExample) |
| NZ (1) | NZ706884A (enExample) |
| PH (1) | PH12015500771B1 (enExample) |
| PL (1) | PL2914624T3 (enExample) |
| PT (1) | PT2914624T (enExample) |
| RS (1) | RS56075B1 (enExample) |
| SG (1) | SG11201502749VA (enExample) |
| SI (1) | SI2914624T1 (enExample) |
| WO (1) | WO2014068012A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10028998B2 (en) | 2012-10-30 | 2018-07-24 | Suppremol Gmbh | Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb |
| US10669324B2 (en) | 2012-10-30 | 2020-06-02 | Suppremol Gmbh | Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein |
| EP2796144A1 (en) * | 2013-04-26 | 2014-10-29 | SuppreMol GmbH | Highly concentrated Formulations of soluble Fc receptors |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| EA034176B1 (ru) | 2013-10-16 | 2020-01-14 | Зуппремоль Гмбх | РАСТВОРИМЫЙ Fc-ГАММА РЕЦЕПТОР ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ БУЛЛЕЗНЫХ ЗАБОЛЕВАНИЙ |
| JP6710451B2 (ja) * | 2016-03-31 | 2020-06-17 | 東ソー株式会社 | 改変型組換えＦｃγＲＩＩｂ |
| CN112423900A (zh) * | 2018-06-25 | 2021-02-26 | 巴斯夫涂料有限公司 | 生产优化涂层的方法和使用所述方法可获得的涂层 |
| CN111454914A (zh) * | 2019-01-18 | 2020-07-28 | 嘉兴安宇生物科技有限公司 | 一种腺病毒快速纯化方法 |
| WO2024092031A1 (en) | 2022-10-25 | 2024-05-02 | Seismic Therapeutic, Inc. | VARIANT IgG FC POLYPEPTIDES AND USES THEREOF |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69434447T2 (de) | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | Für die gentherapie verwendbare plasmide |
| JPH11509088A (ja) | 1995-06-23 | 1999-08-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 血管内皮増殖因子受容体をコードする遺伝子の転写調節 |
| US6849719B2 (en) | 1997-09-17 | 2005-02-01 | Human Genome Sciences, Inc. | Antibody to an IL-17 receptor like protein |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| DE10157290A1 (de) * | 2001-11-22 | 2003-06-05 | Max Planck Gesellschaft | Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2004293184B2 (en) | 2003-11-26 | 2010-12-16 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Substance binding human IgG Fc receptor IIb |
| DE602006020333D1 (de) | 2005-12-13 | 2011-04-07 | Suppremol Gmbh | Multimere fc-rezeptor-polypeptide |
| EP1870442A1 (en) * | 2006-06-19 | 2007-12-26 | DSMIP Assets B.V. | Air drying resin and composition |
| EP1870422A1 (en) | 2006-06-20 | 2007-12-26 | SuppreMol GmbH | Means for the treatment of diseases characterized by an excessive immune reaction |
| CN102131517B (zh) | 2008-06-27 | 2014-12-17 | 津莫吉尼蒂克斯公司 | 可溶性杂合Fc γ受体和相关的方法 |
| US10669324B2 (en) | 2012-10-30 | 2020-06-02 | Suppremol Gmbh | Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein |
| US10028998B2 (en) | 2012-10-30 | 2018-07-24 | Suppremol Gmbh | Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb |
-
2012
- 2012-10-30 US US13/663,527 patent/US10028998B2/en active Active
-
2013
- 2013-10-30 AU AU2013340831A patent/AU2013340831B2/en active Active
- 2013-10-30 HU HUE13798258A patent/HUE032786T2/en unknown
- 2013-10-30 HR HRP20170894TT patent/HRP20170894T1/hr unknown
- 2013-10-30 MX MX2015005266A patent/MX359802B/es active IP Right Grant
- 2013-10-30 DK DK13798258.3T patent/DK2914624T3/en active
- 2013-10-30 RS RS20170593A patent/RS56075B1/sr unknown
- 2013-10-30 JP JP2015538506A patent/JP6423351B2/ja active Active
- 2013-10-30 KR KR1020157013516A patent/KR102170674B1/ko active Active
- 2013-10-30 IN IN3206DEN2015 patent/IN2015DN03206A/en unknown
- 2013-10-30 WO PCT/EP2013/072741 patent/WO2014068012A1/en not_active Ceased
- 2013-10-30 CA CA2887164A patent/CA2887164C/en active Active
- 2013-10-30 ES ES13798258.3T patent/ES2628049T3/es active Active
- 2013-10-30 LT LTEP13798258.3T patent/LT2914624T/lt unknown
- 2013-10-30 MY MYPI2015001106A patent/MY173686A/en unknown
- 2013-10-30 BR BR112015008815A patent/BR112015008815A2/pt not_active Application Discontinuation
- 2013-10-30 CN CN201380056738.3A patent/CN104918955B/zh active Active
- 2013-10-30 PT PT137982583T patent/PT2914624T/pt unknown
- 2013-10-30 PL PL13798258T patent/PL2914624T3/pl unknown
- 2013-10-30 EP EP13798258.3A patent/EP2914624B1/en active Active
- 2013-10-30 SI SI201330679A patent/SI2914624T1/sl unknown
- 2013-10-30 EA EA201590845A patent/EA033437B9/ru not_active IP Right Cessation
- 2013-10-30 SG SG11201502749VA patent/SG11201502749VA/en unknown
- 2013-10-30 NZ NZ706884A patent/NZ706884A/en unknown
-
2015
- 2015-04-07 PH PH12015500771A patent/PH12015500771B1/en unknown
- 2015-04-29 CL CL2015001127A patent/CL2015001127A1/es unknown
- 2015-04-29 IL IL238528A patent/IL238528A/en active IP Right Grant
-
2018
- 2018-08-09 JP JP2018149864A patent/JP2018186833A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018186833A5 (enExample) | ||
| JP2018100276A5 (enExample) | ||
| JP2021502979A5 (enExample) | ||
| IL276830A (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2019142968A5 (enExample) | ||
| SG11202007074PA (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| EP3878863A4 (en) | ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE | |
| ZA202103061B (en) | Anti-cldn18.2 antibody and uses thereof | |
| ZA202106880B (en) | Anti-claudin 18.2 antibody and application thereof | |
| JP2017048194A5 (enExample) | ||
| MY209489A (en) | Antibody against human il-4ra and use thereof | |
| JPWO2020148954A5 (enExample) | ||
| JP2018064407A5 (enExample) | ||
| JP2017140920A5 (enExample) | ||
| LT3658140T (lt) | Aprocitentano ir kitų veikliųjų sudedamųjų dalių deriniai, skirti atsparios hipertenzijos gydymui | |
| JP2017501211A5 (enExample) | ||
| JP2018127649A5 (enExample) | ||
| JP2021129286A5 (enExample) | ||
| LT3979827T (lt) | Maistinė kompozicija, apimanti 2‘-fukozillaktozę ir 3‘-galaktozillaktozę | |
| EP3789382A4 (en) | PROCESS FOR THE PRODUCTION OF 4,5-DIHYDROISOXAZOLE 5,5-DISUBSTITUTED | |
| JP2019512693A5 (enExample) | ||
| CN110809579A (zh) | 多肽的药学可接受的盐及其应用 | |
| JP2020531778A5 (enExample) | ||
| JP2019218304A5 (enExample) | ||
| JP2017128606A5 (enExample) |